BetterLife Pharma Company Description
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada.
It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections.
The company offers a product pipeline that includes BETR-001, a non-hallucinogenic neuroplastogen based on 2-bromo-lysergic acid diethylamide (2-bromo-LSD), intended for the treatment of major depressive disorder, anxiety disorder, neuropathic pain, and other neuropsychiatric and neurological conditions.
It is also developing MM-001, a topical cream formulation of interferon-alpha 2b, which has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation that has completed Phase II clinical trials for the treatment of COVID-19 and other respiratory viral infections.
The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019.
BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Ahmad Doroudian |
Contact Details
Address: 1275 West 6th Avenue Vancouver, BC V6H 1A6 Canada | |
| Website | abetterlifepharma.com |
Stock Details
| Ticker Symbol | BETRF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | February - January |
| Reporting Currency | CAD |
| ISIN Number | CA08772P2026 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ahmad Doroudian Ph.D. | Founder, Chief Executive Officer and Director |
| Moira Ong C.A., CPA, CFA | Chief Financial Officer |
| Dr. Hooshmand Sheshbaradaran Ph.D. | Chief Operating Officer |
| Dr. Stephen Sangha | Corporate Development Advisor and Director |
| Douglas L. Drysdale | Executive Chairman and Member of Scientific Advisory Board |
| Scott Rudge Ph.D. | Head of CMC |